Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is reporting third quarter earnings results on Tuesday 4th August 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.84 per share.
For the full year, analysts predict revenues of $ 138.40 million, while looking forward to loss of $ 1.36 per share.
Previous Quarter Performance
Enanta Pharmaceuticals, Inc. posted loss for the second quarter of $ 0.30 per share, from the revenue of $ 27.62 million. The quarterly revenues dropped 30.31 percent compared with the same quarter last year. Street analysts expected Enanta Pharmaceuticals, Inc. to report loss of $ 0.88 per share on revenue of $ 27.55 million for the second quarter. The bottom line results beat street analysts by $ 0.58 or 65.91 percent, at the same time, top line results outshined analysts by $ 0.07 million or 0.25 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Enanta Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of ENTA was $ 47.05, representing a 22.53 % increase from the 52 week low of $ 38.40 and a 37.81 % decrease over the 52 week high of $ 75.66.
The company has a market capital of $ 941.20 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ENTA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Enanta Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.enanta.com
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc.
